News | February 22, 2022
Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma
The transaction as well as the open offer is expected to be completed by June this year.
The transaction as well as the open offer is expected to be completed by June this year.
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
To be marketed by Strides Pharma Inc. in the US market
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Subscribe To Our Newsletter & Stay Updated
